OPVANOX-ARDS · Advanced pulmonary vascular monitoring for optimum Nitric Oxide delivery in acute respiratory distress syndrome. Expanding Nitric Oxide applications
Horizon 2020 — Marie Skłodowska-Curie Actions
- Duration
- 2018-05-01 → 2020-04-30
- EU contribution
- €158,122
- Participants
- 1
- Scheme
- MSCA-IF-EF-SE
Lines connect the coordinator with its partners.
Results in brief
Advanced pulmonary vascular monitoring for optimum Nitric Oxide delivery in acute respiratory distress syndrome. Expanding Nitric Oxide applications
This project is framed within the therapies for acute respiratory distress syndrome (ARDS), particularly, the efficacy of the use of inhaled nitric oxide (iNO). This syndrome has a high mortality and most of the disease management are based on mechanical ventilation. In patients with ARDS, iNO improves gas exchange and pulmonary hemodynamic but has not proven to decrease mortality nor relevant clinical outcomes. A better description of the effects of iNO on pulmonary vascular function and how this can be used for a better characterization of the response to this therapy is needed. This can also lead to a better discrimination of those patients that could benefit from the iNO treatment but the improvement in the patient monitoring during the iNO therapy is a key factor. The impact on society of this study is based on the fact the ARDS has a high mortality and that this syndrome is very frequent in intensive care units and results as a complication of several pulmonary and non-pulmonary diseases. Complementary therapies as iNO could decrease not only mortality but also the number of days patient is under mechanical ventilation and consequently the complications related with ARDS. The high impact of this study is not only from the clinical point of view but also from an economical one because the cost for hospitals and healthcare systems. Furthermore, a better selection of patients in which iNO is used can lead to resources optimisation, decreasing the expenditures in patients with low probability of good response to this therapy. The development of tools to improve iNo therapy and patient selection can be strategically relevant for companies working in this field and is beneficial for the entrepreneurship. The main objective of this study was to define bedside parameters to guide and monitor pulmonary vascular function during iNO delivery in ARDS. Specific objectives are: - To explore bedside physiologically driven parameters and monitoring tools to control iNO delivery for treating pulmonary vascular dysfunction in ARDS, - To evaluate the pulmonary vascular effect of NO in ARDS by means of advanced imaging tools, - To propose new algorithms based in physiologic variables for selecting patient for NO application, - To set the most extended clinical application of iNO as a treatment for pulmonary vascular dysfunction and prevention of right ventricle failure in ARDS patients, - To describe the dose response of iNO for the components developed to evaluate pulmonary vascular function, - To explore new therapeutic applications of NO. The conclusion of the study indicates it is possible to monitor parameters of the patient that represent the effect of the iNO on the patient efficiently. The results will conduct to an important improvement in patient safety for a potential use of iNO in hospital and more importantly in domiciliary condition. The results permit to optimise the use of iNO in those patients that respond properly to the treatment. Additionally, understanding better the pulmonary physiology is also key for the next set of experiments. In summary, these results are key for the design of more secure devices for also extending the application of iNO in other segment of patients.
Data: CORDIS, © European Union
Project objective
Acute respiratory distress syndrome (ARDS) is the most severe form of respiratory failure. Pulmonary vascular dysfunction during ARDS increases mortality and therapies focused in improving pulmonary vascular mechanics could improve patient prognosis. Inhaled Nitric Oxide (NO), improves pulmonary vascular mechanics, but despite of this effect, has not proven to improve outcomes in ARDS. One of the most representative problems is the lack of information of the quantitative dose used and all consequences that this uncontrolled administration entails. In this project we aim to establish bedside physiologic variables and algorithms to guide efficient NO delivery during ARDS. It will involve the collaboration between an enterprise that has developed a new NO delivering system and is looking for expanding its applications and a researcher with expertise in physiology, imaging and biologic variables monitoring. As a result of this collaboration, the company will gain a quantitative way of determining the treatment efficiency that could be used in this and other applications, a more patient-oriented and physiology-focused approach for this product and the researcher will acquire skills for turning his career from the academy to the industry side. This research will combine edge technology to define bedside tools for patients monitoring with the application of this information for improving the performance of the delivery system. Clinically relevant imaging tools such as Magnetic Resonance Imaging and Positron Emission Tomography, and pulmonary artery pressure waveform advanced analysis as well as other non or minimum invasive tools will be studied in animal models. Software, algorithm or dedicated products will be proposed for incorporation into the gas delivery system or clinical monitors for improving patient safety. We are expecting a clear benefit to emerging European-based technologies that make our companies more competitive and well-positioned in a worldwide business.
Original text from CORDIS.
Participants
- INGENIERIA Y TECNICAS CLINICAS SA · ARGANDA DEL REY - MADRIDCoordinatorSpain
Links
Data: CORDIS, © European Union
